- recruitingHuman Pharmacology (Phase I)- Other
An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants with Schizophrenia
This study is looking at a new way to give a medicine called olanzapine, which is used for schizophrenia, to see if it works as well as the usual pills. It's a very early-stage study to check how the body uses the new medicine compared to the old one.
Germany · Spain · France - recruitingTherapeutic exploratory (Phase II)
EVALUATION OF THE EFFICACY OF TOLCAPONE AS A GENOTYPE-BASED TARGETED COGNITIVE ENHANCER IN SCHIZOPHRENIA, BASED ON THE POLYMORPHISM RS4680
This study looks at a medicine called Tasmar to see if it can improve thinking skills in people with schizophrenia. Researchers are focusing on individuals with a specific genetic marker (rs4680) to understand how the medicine affects their brain and daily function.
Spain - recruitingTherapeutic confirmatory (Phase III)
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)
This study is looking at the long-term safety of a new medicine called Iclepertin for people with schizophrenia. It's for those who have already taken part in earlier studies of this medicine. We want to see how safe it is over a longer period.
Netherlands · Croatia · Finland - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
This study is looking into a new medication called KarXT for adults with schizophrenia who aren't getting enough relief from their current treatments. It aims to see if KarXT can help reduce symptoms, compared to a dummy pill, over a 6-week period.
Bulgaria - recruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
This study is looking at the long-term safety of a new medicine called KarXT for people with schizophrenia. It's a follow-up to earlier studies, helping us understand how safe it is when used for a longer time, and if there are any side effects.
Bulgaria - recruitingTherapeutic exploratory (Phase II)
Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine?
This study looks at whether a medicine called semaglutide (often known as Ozempic) can help people with schizophrenia on certain antipsychotic medicines. Researchers want to see if it can prevent or slow down problems with blood sugar, like pre-diabetes or diabetes, in these patients.
Denmark - recruitingHuman Pharmacology (Phase I)- Other
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CLE-905-AG, a M1/M4 Muscarinic Agonist when administered alone or in conjunction with a Peripheral Muscarinic antagonist, in Healthy Participants
This study is testing a new medicine, CLE-905-AG, for people with schizophrenia. It's a very early-stage trial looking at how safe the medicine is, how well the body handles it, and how much is needed. Healthy volunteers are taking part to help us learn more before it's given to patients.
France - recruitingPhase I
Evaluation of NBI-1117570 in adults with stable schizophrenia
This study is testing a new medicine, NBI-1117570, for adults who have schizophrenia and are feeling stable. We want to see if it's safe, how much of it stays in the body, and what effects it has. The full details will be released in about two and a half years after the study finishes.
United Kingdom · England - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intramuscular Injection in Healthy Subjects
This study is comparing two medicines for schizophrenia, LY03010 and Xeplion®, to see if they work the same way in the body. It involves healthy volunteers getting a single injection to help us understand how the new medicine is absorbed.
Portugal - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia
This study is looking at a new medicine called Valbenazine for people with schizophrenia. It aims to see if adding Valbenazine to existing treatments helps reduce symptoms and improve daily life over 10 weeks. Some people will get the medicine, others a dummy pill.
Bulgaria · Croatia · Czechia - recruitingTherapeutic exploratory (Phase II)
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia
This study is looking at a new medicine called Emraclidine for adults with schizophrenia over 52 weeks. It aims to see if the medicine is safe and if people can take it for a long time without too many problems.
Hungary · Bulgaria - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment in Subjects with Schizophrenia
This study is testing a new medicine, Valbenazine, for people with schizophrenia. Researchers want to see if it helps improve symptoms when taken alongside other treatments, how safe it is, and if people can tolerate it well.
Romania · Czechia · Spain - active not recruitingNA
Cognitive Remediation for Social Cognition in Schizophrenia and Related Disorders
This study looks at a new online programme called RC2S+ for people with schizophrenia and similar conditions. It aims to see if using this programme distantly is practical and helpful for improving social thinking skills.
Canada - recruitingNA
Group Intervention for Romantic Relationships in Young Adults With Severe Mental Illness
This study helps adults with severe mental illness improve their romantic and social skills. It's a group program called "Better Together" that aims to reduce loneliness and build confidence for healthy relationships, supported by mental health experts.
France - recruitingPHASE3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
This study looks at the long-term safety of a new medicine, KarXT, for people with schizophrenia whose current treatment isn't working well enough. It's for those who have already started in a previous related study.
United States · Bulgaria · Czechia - recruitingNA
EEG Microstates Across At-Risk Mental States
This study looks at brain activity in young people (15-30) with or at risk of certain mental health conditions like depression, psychosis, and autism. It uses special scans and tests to understand how brain patterns might be linked to these conditions and overall well-being.
France - authorisedTherapeutic exploratory (Phase II)
A Phase 2a, Randomized, Participant- and Investigator blinded, Parallel-group, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults with DSM-5 Schizophrenia (STAR-1)
This study is testing a new medicine, GXV813, for adults in hospital with schizophrenia. Researchers want to see if it's safe, how well people tolerate it, and if it helps with symptoms after six weeks compared to a dummy pill. It's an early-stage study to understand the medicine better.
Bulgaria - recruitingNA
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
This study uses virtual reality games to explore how people with schizophrenia and bipolar disorder experience time differently. Researchers hope to better understand these differences, which might help predict who could develop psychosis.
France - not yet recruitingNA
The Personalized Psychological Treatment for Psychosis
This study is testing a new, more tailored type of talking therapy called Personalized Metacognitive Training (P-MCT) for people with psychosis that involves delusions. We want to see if this personalized approach works better than the standard therapy to help people feel and cope better.
Chile · France · Germany - active not recruitingPHASE2
Enhancing Recovery in Early Schizophrenia
This study is testing a natural compound called cannabidiol (from cannabis plants, but without the 'high') to see if it can help people with early schizophrenia as an add-on to their usual medication, reduce side effects, and improve long-term recovery.
Germany - recruitingNA
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
This study looks into two specific types of schizophrenia, called hebephrenia and periodic catatonia. We want to see if these types have different symptoms, thinking patterns, and brain activity to help doctors find better, more personal treatments in the future.
France - recruitingNA
Skills for Wellness
This study, 'Skills for Wellness', helps young people (9-21) at high risk of severe mental illness like schizophrenia or bipolar disorder. It tests a new talking therapy called maCBT to prevent these conditions by teaching skills to manage early warning signs like anxiety or unusual experiences.
Canada - active not recruiting
ERG Components in Schizophrenia and Bipolar Disorder Type I
This study uses a special eye test called an ERG to help tell the difference between schizophrenia and bipolar disorder. Researchers want to see if patterns in eye signals can help doctors diagnose these conditions more easily using a new computer program.
United States · Australia · Canada - authorisedHuman Pharmacology (Phase I)- First administration to humans
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers
This early-stage study is looking for healthy volunteers to test a new medicine called ST-905-AG1. Doctors want to see how safe it is, how the body handles it, and what it does in healthy people. This helps them understand it better before giving it to patients with schizophrenia.
France - active not recruitingNA
Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia
This study looks at a special type of brain stimulation, called Paired Associative Stimulation (PAS), in people with schizophrenia. Researchers want to see if PAS can improve how brain cells communicate and help with memory and thinking skills.
Canada - recruitingNA
Role of Inferior Colliculi in Auditory Hallucinations
This study uses brain scans to understand how people with schizophrenia hear voices. Researchers are especially looking at a tiny part of the brain called the inferior colliculi to see if it plays a role in these hallucinations. The goal is to better understand why they happen.
France - recruitingNA
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
This study looks at whether problems with how the brain uses insulin might explain some thinking and memory issues, as well as common health problems like obesity and diabetes, in people with schizophrenia. Researchers will use a special scan after giving insulin through the nose to see how the brain reacts.
Canada - recruitingNA
Cognitive Remediation in Forensic Mental Health Care
This study looks at a special kind of mental exercise called 'cognitive remediation' for people in forensic mental health care. It aims to see if these exercises can improve thinking skills, everyday abilities, and mental well-being in patients dealing with conditions like schizophrenia or ADHD.
Canada - recruitingNA
Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis
This study looks at a new virtual reality (VR) program to help people with conditions like schizophrenia improve their thinking and social skills. It aims to see if this VR therapy can make a real difference in daily life.
Canada - recruitingNA
Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial
This study looks into using ongoing electrical brain treatment (maintenance ECT) for people with severe schizophrenia who haven't improved with usual medicines, including clozapine. It wants to see if this treatment helps prevent relapses and improves their quality of life.
Germany - recruitingPHASE3
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
This study looks at a medicine called KarXT for young people aged 5 to 17. It checks how safe and tolerable it is over a long time for schizophrenia and irritability linked to autism. It's for those who have already started treatment in previous related studies.
United States · Argentina · Canada - recruitingNA
Outcomes From Remediation and Behavioural Intervention Techniques
This study looks at how well different talking therapies, like CBT for psychosis and brain training, work for people with conditions like schizophrenia. Researchers want to find out who benefits most from each therapy, or a combination, to help improve daily life.
Canada - recruitingNA
Magnetic Seizure Therapy for Schizophrenia - Trial
This study compares a new treatment called Magnetic Seizure Therapy (MST) with standard electroconvulsive therapy (ECT) for people with schizophrenia that hasn't responded to other treatments. It aims to see if MST is as good as ECT and easier to cope with.
Canada - recruitingNA
EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia
This study looks at how people with schizophrenia predict events using touch, and how this relates to their sense of self. Researchers hope to find new ways to identify those at risk of developing psychosis earlier, to help them get the right support.
France - authorisedHuman Pharmacology (Phase I)- Bioequivalence Study
A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia
This study is looking at a new version of a medication for schizophrenia. It compares how this new version is handled by the body to an existing medication, to see if they work in a similar way after several doses.
Bulgaria · Croatia · Portugal - authorisedTherapeutic confirmatory (Phase III)
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 years of age)
This study is looking into a new medicine called KarXT for teenagers (aged 13-17) who have schizophrenia. Researchers want to see if KarXT can help improve symptoms and if it is safe to use. Some teens will get KarXT, and others will get a dummy medicine.
Romania - recruitingPHASE3
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
This study is testing a new medicine, KarXT, to see if it can help prevent symptoms from coming back in people with schizophrenia. It's a late-stage trial comparing KarXT to a dummy pill to understand its effects better.
United States · Argentina · Bulgaria - recruitingPHASE2
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
This study is testing a new medicine, NBI-1117570, for adults aged 18-55 who are in hospital because of a flare-up of their schizophrenia symptoms. It aims to see if the new medicine helps improve these symptoms compared to a dummy pill.
Bulgaria · Romania · United Kingdom - recruiting
Energetics and Glutamate in Schizophrenia
This study compares brain activity and chemistry in healthy people and those with schizophrenia. Using special scans, researchers want to see if there are differences in how the brain uses sugar and other chemicals, which could help us understand schizophrenia better.
United Kingdom